Articles

  • 2 weeks ago | ajmc.com | Ajai Chari |Kyle Munz

    In recent years, dramatic clinical trial results in multiple myeloma have dominated plenary sessions and news conferences at major cancer meetings.

  • 3 weeks ago | ajmc.com | Kyle Munz |Andrew M. Evens

    Collaborative efforts between pediatric and adult oncologists are helping shape a bright future for adult and young adult (AYA) patients with Hodgkin and non-Hodgkin lymphoma alike.

  • 4 weeks ago | businessandamerica.com | Kyle Munz

    US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.

  • 4 weeks ago | ajmc.com | Kyle Munz |Antoine Keller

    US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.

  • 4 weeks ago | ajmc.com | Kyle Munz |Naim Alkhouri

    Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →